Pharmacist Resources

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

REVLIMID REMS® information for certified pharmacies

REVLIMID is only dispensed from REVLIMID REMS® program certified pharmacies.

As a REVLIMID REMS® certified pharmacy, you must follow the requirements of the REVLIMID REMS® program. You may download a guide to the program, a checklist for counseling patients, and the full prescribing information below.


The Celgene REMS Pharmacy Portal

In addition to calling the Celgene Customer Care Center to obtain a confirmation number for a prescription, eligible pharmacies can obtain confirmation numbers using the Celgene REMS Pharmacy Portal at CelgeneREMSPharmacyPortal.com. Contact your Celgene Account Manager to see if your pharmacy is eligible.


Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods:

REPORTING TO CELGENE

Online:

Email:

Telephone:

1-908-673-9667

Toll-free:

1-800-640-7854 (Global Drug Safety & Risk Management) or
1-888-423-5436 (Celgene Customer Care Center)

Fax:

1-908-673-9115

Mail to:

Global Drug Safety & Risk Management
Celgene Corporation
86 Morris Avenue
Summit, New Jersey 07901

Other:

Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management

REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of REVLIMID and
any suspected pregnancy occurring during the treatment with REVLIMID may also be reported
to the FDA MedWatch Reporting System using any of the following methods:

Online:

Telephone:

1-800-FDA-1088

Fax:

1-800-FDA-0178

Mail to:

MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: